The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mastocytoma

  • On the other hand, the P815 mastocytoma was much less responsive to IL-1 therapy, in that it failed to undergo complete regression in response to doses of IL-1 capable of causing regression of the L5178Y lymphoma [1].
  • In contrast to the progressive outgrowth of all wild-type (B7-) tumors in unimmunized syngeneic mice, four immunogenic tumors, lymphoma RMA, EL4, mastocytoma P815, and melanoma E6B2, regressed completely when transduced with the B7 gene [2].
  • This increase, in direct proportion to the number of mastocytoma cells transferred, also occurred when Escherichia coli lipopolysaccharide (a T-cell independent antigen) was used to immunize animals given spleen cells from normal mice and mastocytoma cells [3].
  • In all cases the lesional mast cells expressed SERPINB6, and, in diffuse cutaneous mastocytosis and mastocytoma, SERPINB6 was expressed by a substantially higher number of mast cells when compared with tryptase [4].
  • Ascites fluid accumulation accompanying a mastocytoma or L1210 murine tumor is significantly retarded following the i.p. or s.c. injection of moderate quantities of pepstatin, a known acid protease inhibitor [5].

High impact information on Mastocytoma


Chemical compound and disease context of Mastocytoma


Biological context of Mastocytoma


Anatomical context of Mastocytoma


Gene context of Mastocytoma

  • Mutation at the equivalent position in the murine c-kit gene, involving a substitution of tyrosine for aspartic acid (D814Y), has been described in the mouse mastocytoma cell line P815 [23].
  • The involvement of a host B7 family costimulator molecule in the rejection of immunogenic tum- variants of the mastocytoma P815 was explored [24].
  • Two genes encoding NDST isozymes have been described, one from rat liver (NDST1) and another from murine mastocytoma (NDST2) [25].
  • We investigated the cytolytic mechanism by CD4+ T cells in anti-CD3 mAb-induced redirected cytotoxicity against a murine Fc receptor-bearing mastocytoma (P815) transfected with either CD80 or CD137 ligand (CD137L) [26].
  • Here we show that overexpression of the Bcl-2 protein in the murine mastocytoma line P815 or in concanavalin A-activated splenocytes suppresses apoptotic cell death induced by allospecific primary cytotoxic T lymphocytes (CTL) in which only the Fas lytic pathway was functional [27].

Analytical, diagnostic and therapeutic context of Mastocytoma

  • Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma [28].
  • O-Sulfotransferases involved in heparin biosynthesis were purified > or = 10,000-fold from detergent extracts of mouse mastocytoma tissue by sequential chromatographies on DEAE-Sephacel, heparin-agarose, blue Sepharose, and 3',5'-ADP-Sepharose [29].
  • Pulse-labelling of mouse mastocytoma cell cultures, established from ascites fluid, with inorganic [35S]sulphate for 1 h yielded labelled heparin proteoglycan containing polysaccharide chains of Mr 60,000-100,000 [30].
  • The P91 mutant clone of P815 mastocytoma (DBA/2 origin) expresses potent tumor-specific transplantation antigens (TSTA) that elicit vigorous immune responses in the syngeneic host [31].
  • Our analyses by flow cytometry show that NTA-DTDA can be incorporated into PMV prepared from murine P815 mastocytoma and that the incorporated NTA-DTDA permits anchoring or "engraftment" onto the vesicle surface of hexahistidine-tagged proteins such as recombinant forms of the costimulatory molecules B7.1 and CD40 [32].


  1. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. North, R.J., Neubauer, R.H., Huang, J.J., Newton, R.C., Loveless, S.E. J. Exp. Med. (1988) [Pubmed]
  2. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellström, I., Hellström, K.E. J. Exp. Med. (1994) [Pubmed]
  3. Altered immunologic responsiveness in mastocytoma-bearing mice. Kamo, I., Patel, C., Friedman, H. J. Natl. Cancer Inst. (1976) [Pubmed]
  4. Intracellular serpin SERPINB6 (PI6) is abundantly expressed by human mast cells and forms complexes with beta-tryptase monomers. Strik, M.C., Wolbink, A., Wouters, D., Bladergroen, B.A., Verlaan, A.R., van Houdt, I.S., Hijlkema, S., Hack, C.E., Kummer, J.A. Blood (2004) [Pubmed]
  5. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation. Greenbaum, L.M., Grebow, P., Johnston, M., Prakash, A., Semente, G. Cancer Res. (1975) [Pubmed]
  6. A model of cell cycle control: effects of thymidine on synchronous cell cultures. Thomas, D.B., Lingwood, C.A. Cell (1975) [Pubmed]
  7. Enzymatic assembly of slow reacting substance. Jakschik, B.A., Lee, L.H. Nature (1980) [Pubmed]
  8. A naturally occurring soluble isoform of murine Fas generated by alternative splicing. Hughes, D.P., Crispe, I.N. J. Exp. Med. (1995) [Pubmed]
  9. The beta subunit of the Fc epsilon RI is associated with the Fc gamma RIII on mast cells. Kurosaki, T., Gander, I., Wirthmueller, U., Ravetch, J.V. J. Exp. Med. (1992) [Pubmed]
  10. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. Azuma, M., Cayabyab, M., Buck, D., Phillips, J.H., Lanier, L.L. J. Exp. Med. (1992) [Pubmed]
  11. Stimulus specificity of the generation of leukotrienes by dog mastocytoma cells. Goetzl, E.J., Phillips, M.J., Gold, W.M. J. Exp. Med. (1983) [Pubmed]
  12. Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. Sekizawa, K., Caughey, G.H., Lazarus, S.C., Gold, W.M., Nadel, J.A. J. Clin. Invest. (1989) [Pubmed]
  13. Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. Fang, K.C., Raymond, W.W., Lazarus, S.C., Caughey, G.H. J. Clin. Invest. (1996) [Pubmed]
  14. Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice. Warrington, R.C., Cheng, I., Fang, W.D. J. Natl. Cancer Inst. (1987) [Pubmed]
  15. Elevated level of enzymatic DNA methylation in cells treated with 1-beta-D-arabinofuranosylcytosine. Boehm, T.L., Drahovsky, D. Cancer Res. (1982) [Pubmed]
  16. Human beta 2-microglobulin specifically enhances cell-surface expression of HLA class I molecules in transfected murine cells. Perarnau, B.M., Gillet, A.C., Hakem, R., Barad, M., Lemonnier, F.A. J. Immunol. (1988) [Pubmed]
  17. Biosynthesis of heparin. Concerted action of late polymer-modification reactions. Jacobsson, I., Lindahl, U. J. Biol. Chem. (1980) [Pubmed]
  18. Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I. Wolters, P.J., Raymond, W.W., Blount, J.L., Caughey, G.H. J. Biol. Chem. (1998) [Pubmed]
  19. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. Salazar-Onfray, F., Charo, J., Petersson, M., Freland, S., Noffz, G., Qin, Z., Blankenstein, T., Ljunggren, H.G., Kiessling, R. J. Immunol. (1997) [Pubmed]
  20. Receptors for T cell-replacing factor/interleukin 5. Specificity, quantitation, and its implication. Mita, S., Harada, N., Naomi, S., Hitoshi, Y., Sakamoto, K., Akagi, M., Tominaga, A., Takatsu, K. J. Exp. Med. (1988) [Pubmed]
  21. Early transmembrane events in alloimmune cytotoxic T-lymphocyte activation as revealed by stopped-flow fluorometry. Utsunomiya, N., Tsuboi, M., Nakanishi, M. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  22. Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. Tsujimura, T., Morii, E., Nozaki, M., Hashimoto, K., Moriyama, Y., Takebayashi, K., Kondo, T., Kanakura, Y., Kitamura, Y. Blood (1996) [Pubmed]
  23. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Piao, X., Paulson, R., van der Geer, P., Pawson, T., Bernstein, A. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  24. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. Gajewski, T.F., Fallarino, F., Uyttenhove, C., Boon, T. J. Immunol. (1996) [Pubmed]
  25. Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/ N-sulfotransferase family. Aikawa, J., Esko, J.D. J. Biol. Chem. (1999) [Pubmed]
  26. Rapid induction of CD95 ligand and CD4+ T cell-mediated apoptosis by CD137 (4-1BB) costimulation. Ebata, T., Mogi, S., Hata, Y., Fujimoto, J.I., Yagita, H., Okumura, K., Azuma, M. Eur. J. Immunol. (2001) [Pubmed]
  27. Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Schröter, M., Lowin, B., Borner, C., Tschopp, J. Eur. J. Immunol. (1995) [Pubmed]
  28. Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma. Schenken, L.L., Hagemann, R.F., Burholt, D.R., Lesher, S. J. Natl. Cancer Inst. (1976) [Pubmed]
  29. Biosynthesis of heparin. Different molecular forms of O-sulfotransferases. Wlad, H., Maccarana, M., Eriksson, I., Kjellén, L., Lindahl, U. J. Biol. Chem. (1994) [Pubmed]
  30. Degradation of heparin proteoglycan in cultured mouse mastocytoma cells. Jacobsson, K.G., Lindahl, U. Biochem. J. (1987) [Pubmed]
  31. Spontaneous immune rejection of intraocular tumors in mice. Niederkorn, J.Y., Meunier, P.C. Invest. Ophthalmol. Vis. Sci. (1985) [Pubmed]
  32. A novel approach for modifying tumor cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumor immunotherapy. van Broekhoven, C.L., Altin, J.G. Int. J. Cancer (2002) [Pubmed]
WikiGenes - Universities